Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
Eric Yuk Fai WanZoey C T WongVincent K C YanCeline S L ChuiFrancisco T T LaiXue LiIan C K WongEsther W Y ChanPublished in: Diabetes, obesity & metabolism (2024)
The use of nirmatrelvir-ritonavir may be preferred to molnupiravir for COVID-19 patients with T2DM and without contraindication to either treatment.